📊 FBLG Key Takeaways
Is FibroBiologics, Inc. (FBLG) a Good Investment?
FibroBiologics is a pre-revenue biotech company facing severe financial distress with accelerating losses (-67% YoY), negative operating cash flow of -$4.4M annually, and minimal cash runway (~4 months) given only $1.5M cash against $4.3M debt. The combination of zero revenue, deteriorating profitability, high leverage (1.65x debt/equity), and substantial cash burn with no visible capital deployment for R&D indicates imminent liquidity challenges without successful financing or commercialization.
FibroBiologics appears to be a pre-revenue biotech with no demonstrated commercial traction and deeply negative operating economics. The balance sheet still shows positive equity and solid near-term current liquidity, but cash burn is far above cash on hand, implying a strong dependence on external financing. Fundamentally, this is a high-risk profile with weak profitability trends, poor cash flow quality, and limited financial durability absent new capital or clinical/commercial progress.
FibroBiologics, Inc. Key Strengths (FBLG)
- Positive current ratio of 1.59x provides near-term liquidity cushion
- Minimal capex requirement ($0) reduces ongoing capital needs for operations
- Recent insider activity (8 Form 4 filings) may indicate management confidence in pipeline
- Current and quick ratios of 3.61x indicate acceptable near-term balance sheet liquidity
- Positive stockholders' equity of $6.16M means the company is not yet balance-sheet insolvent
- Debt/equity of 0.70x is not extreme for a development-stage company despite ongoing losses
FBLG Stock Risks: FibroBiologics, Inc. Investment Risks
- Critical cash runway of approximately 4 months at current burn rate creates imminent solvency risk
- No revenue generation with mounting operating losses suggests commercial failure or pre-launch stage with execution uncertainty
- High debt burden ($4.3M) relative to equity base ($2.6M) and cash position creates refinancing/restructuring risk
- Deteriorating financial metrics with net losses worsening 67% YoY indicates worsening operational trends
- Negative interest coverage (-1,267x) demonstrates inability to service debt from operations
- No revenue base or gross profit makes the business entirely dependent on future development success rather than current operations
- Operating cash flow of -$16.39M versus only $4.89M of cash suggests limited runway and likely future capital raises
- Severely negative ROE, ROA, operating income, and interest coverage indicate weak financial health and poor earnings quality
Key Metrics to Watch
- Monthly cash burn rate and remaining cash runway
- Revenue generation timeline and pipeline stage advancement
- Debt refinancing or capital raise activity
- Regulatory approval progress for lead candidates
- Changes in debt/equity ratio and balance sheet leverage
- Cash runway relative to quarterly operating cash burn
- Revenue generation or clinical milestones that can support a path to sustainable operating improvement
FibroBiologics, Inc. (FBLG) Financial Metrics & Key Ratios
💡 AI Analyst Insight
FibroBiologics, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
FBLG Profit Margin, ROE & Profitability Analysis
FBLG vs Healthcare Sector: How FibroBiologics, Inc. Compares
How FibroBiologics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is FibroBiologics, Inc. Stock Overvalued? FBLG Valuation Analysis 2026
Based on fundamental analysis, FibroBiologics, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
FibroBiologics, Inc. Balance Sheet: FBLG Debt, Cash & Liquidity
FBLG Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: FibroBiologics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.34 indicates the company is currently unprofitable.
FBLG Revenue Growth, EPS Growth & YoY Performance
FibroBiologics, Inc. Dividends, Buybacks & Capital Allocation
FBLG SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for FibroBiologics, Inc. (CIK: 0001958777)
📋 Recent SEC Filings
❓ Frequently Asked Questions about FBLG
What is the AI rating for FBLG?
FibroBiologics, Inc. (FBLG) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are FBLG's key strengths?
Claude: Positive current ratio of 1.59x provides near-term liquidity cushion. Minimal capex requirement ($0) reduces ongoing capital needs for operations. ChatGPT: Current and quick ratios of 3.61x indicate acceptable near-term balance sheet liquidity. Positive stockholders' equity of $6.16M means the company is not yet balance-sheet insolvent.
What are the risks of investing in FBLG?
Claude: Critical cash runway of approximately 4 months at current burn rate creates imminent solvency risk. No revenue generation with mounting operating losses suggests commercial failure or pre-launch stage with execution uncertainty. ChatGPT: No revenue base or gross profit makes the business entirely dependent on future development success rather than current operations. Operating cash flow of -$16.39M versus only $4.89M of cash suggests limited runway and likely future capital raises.
What is FBLG's revenue and growth?
FibroBiologics, Inc. reported revenue of N/A.
Does FBLG pay dividends?
FibroBiologics, Inc. does not currently pay dividends.
Where can I find FBLG SEC filings?
Official SEC filings for FibroBiologics, Inc. (CIK: 0001958777) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is FBLG's EPS?
FibroBiologics, Inc. has a diluted EPS of $-1.33.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is FBLG's fundamental grade?
Based on our AI fundamental analysis in June 2026, FibroBiologics, Inc. has a D grade with 86% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is FBLG stock overvalued or undervalued?
Valuation metrics for FBLG: ROE of -192.3% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is FBLG's AI grade for 2026?
Our dual AI analysis gives FibroBiologics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is FBLG's free cash flow?
FibroBiologics, Inc.'s operating cash flow is $-4.4M, with capital expenditures of $0.0.
How does FBLG compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -192.3% (avg: 15%), current ratio 1.59 (avg: 2).
Is FibroBiologics, Inc. carrying too much debt?
FBLG has a debt-to-equity ratio of 1.65x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.59 suggests adequate short-term liquidity.